B of A Securities Upgrades ACADIA Pharmaceuticals to Buy, Maintains Price Target to $29

Benzinga Newsdesk www.benzinga.com Positive 77.6%

Neg 0% Neu 0% Pos 77.6%

B of A Securities analyst Tazeen Ahmad upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Neutral to Buy and maintains the price target from $29 to $29.